tozorakimab (MEDI3506) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tozorakimab (MEDI3506) / AstraZeneca
TILIA, NCT05624450 / 2022-003107-15: Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Recruiting
3
2902
Europe, Canada, Japan, US, RoW
Tozorakimab, MEDI3506, Placebo
AstraZeneca, AstraZeneca AB
Viral Lung Infection and Acute Respiratory Failure
03/25
03/25
OBERON, NCT05166889 / 2021-003797-30: Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

Recruiting
3
1060
Europe, Canada, Japan, US, RoW
Tozorakimab, Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
02/26
05/26
TITANIA, NCT05158387 / 2021-003771-34: Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

Recruiting
3
1060
Europe, US, RoW
Tozorakimab, Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
02/26
05/26
PROSPERO, NCT05742802: Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations ().

Recruiting
3
1596
Europe, Canada, Japan, US, RoW
Tozorakimab 1, Tozorakimab 2, Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
06/26
08/26
MIRANDA, NCT06040086: Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

Recruiting
3
1240
Europe, Canada, Japan, US, RoW
Placebo, Tozorakimab
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
06/26
08/26
2020-001736-95: A Phase 2 Study for the Treatment of COVID 19 in Hospitalised Patients

Ongoing
2
825
Europe
Bemcentinib, MEDI3506, acalabrutinib, Zilucoplan, Heparin, TD139, BGB324, MEDI3506, ACP-196, Capsule, hard, Solution for injection, Solution for injection in pre-filled syringe, Inhalation powder, Heparin
University Hospital Southampton NHS Foundation Trust
COVID 19, COVID 19, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
FRONTIER-3, NCT04570657 / 2020-000789-40: Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

Completed
2
250
Europe, US, RoW
MEDI3506, Placebo
AstraZeneca
Asthma
12/22
02/23
NCT04170543: A Phase 2b Diabetic Kidney Disease Study

Completed
2
609
Canada, Japan, US, RoW
MEDI3506, Placebo, Dapagliflozin
AstraZeneca
Diabetic Kidney Disease
05/23
05/23
FRONTIER-4, NCT04631016 / 2020-000571-20: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

Hourglass Jul 2023 - Dec 2023 : Data from trial for COPD H2 2023
Completed
2
136
Europe, Canada, US, RoW
MEDI3506, Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
05/23
11/23
NCT06304961: A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

Active, not recruiting
1
46
Europe
Tozorakimab
AstraZeneca
Healthy Participants
09/24
09/24

Download Options